Quassinoids: From traditional drugs to new cancer therapeutics

Current Medicinal Chemistry

Volumn 18, Issue 3, 2011, Pages 316-328

  Fiaschetti, G ^a   Grotzer, M A ^a   Shalaby, T ^a   Castelletti, D ^a   Arcaro, A ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anticancer therapeutics; Quassinoids; Simaroubaceae; Tumor

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; BRUCEA JAVANICA EXTRACT; BRUCEANTIN; BRUSATOL; CASPASE 3; CASPASE 8; CASPASE 9; DNA; EURYCOMA LONGIFOLIA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; QUASSINOID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RNA; VASCULOTROPIN;

ARTICLE; CHEMICAL STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE POLARIZATION AND DEPOLARIZATION; NONHUMAN; PROTEIN SYNTHESIS; SIMAROUBACEAE; TRADITIONAL MEDICINE; TUMOR CELL;

EID: 79251517716     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794839205     Document Type: Article

References (72)

1. Lee, K. H. Novel antitumor agents from higher plants. Med. Res. Rev., 1999, 19(6), 569-96.
2. Lee, K. H. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J. Nat. Prod., 2010, 73(3), 500-16.
3. da Rocha, A. B.; Lopes, R. M.; Schwartsmann, G. Natural products in anticancer therapy. Curr. Opin. Pharmacol., 2001, 1(4), 364-9.
4. Curcino Vieira, I. J.; Braz-Filho, R. In: Studies in Natural Products Chemistry; Atta-ur-Rahman, Ed.; Elsevier B. V.: Amsterdam, 2006; pp 433-492.
5. Lau, S. T.; Lin, Z. X.; Liao, Y.; Zhao, M.; Cheng, C. H.; Leung, P. S. Bruceine D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. Cancer Lett., 2009, 281(1), 42-52.
6. Polonsky, J. Quassinoid bitter principles. II. Fortschr. Chem. Org. Naturst., 1985, 47, 221-64.
7. Tamura, S.; Fukamiya, N.; Okano, M.; Tokuda, H.; Aoi, W.; Mukainaka, T.; Nishino, H.; Tagahara, K.; Koike, K. Cancer chemopreventive effect of quassinoid derivatives. Introduction of sidechain to shinjulactone C for enhancement of inhibitory effect on Epstein-Barr virus activation. Cancer Lett., 2002, 185(1), 47-51.
8. von Bueren, A. O.; Shalaby, T.; Rajtarova, J.; Stearns, D.; Eberhart, C. G.; Helson, L.; Arcaro, A.; Grotzer, M. A. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer, 2007, 7, 19.
9. Wani, M. C.; Taylor, H. L.; Thompson, J. B.; Wall, M. E. Plant antitumor agents. XVI. 6alpha-Senecioyloxy-chaparrinone, a new antileukemic quassinoid from Simaba multiflora. Lloydia, 1978, 41(6), 578-83.
10. Guo, Z.; Vangapandu, S.; Sindelar, R. W.; Walker, L. A.; Sindelar, R. D. Biologically active quassinoids and their chemistry: Potential leads for drug design. Curr. Med. Chem., 2005, 12(2), 173-90.
11. Liu, J. H.; Jin, H. Z.; Zhang, W. D.; Yan, S. K.; Shen, Y. H. Chemical constituents of plants from the genus Brucea. Chem. Biodivers., 2009, 6(1), 57-70.
12. Beutler, J. A.; Kang, M. I.; Robert, F.; Clement, J. A.; Pelletier, J.; Colburn, N. H.; McKee, T. C.; Goncharova, E.; McMahon, J. B.; Henrich, C. J. Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition. J. Nat. Prod., 2009, 72(3), 503-6.
13. Fukamiya, N.; Lee, K. H.; Muhammad, I.; Murakami, C.; Okano, M.; Harvey, I.; Pelletier, J. Structure-activity relationships of quassinoids for eukaryotic protein synthesis. Cancer Lett., 2005, 220(1), 37-48.
14. Jin, X.; Jin, H. R.; Lee, D.; Lee, J. H.; Kim, S. K.; Lee, J. J. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxiainducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation. Eur. J. Pharmacol., 2008, 592(1-3), 41-7.
15. Cuendet, M.; Pezzuto, J. M. Antitumor activity of bruceantin: An old drug with new promise. J. Nat. Prod., 2004, 67(2), 269-72.
16. Cuendet, M.; Christov, K.; Lantvit, D. D.; Deng, Y.; Hedayat, S.; Helson, L.; McChesney, J. D.; Pezzuto, J. M. Multiple myeloma regression mediated by bruceantin. Clin. Cancer Res., 2004, 10(3), 1170-9.
17. Kupchan, S. M.; Britton, R. W.; Lacadie, J. A.; Ziegler, M. F.; Sigel, C. W. The isolation and structural elucidation of bruceantin and bruceantinol, new potent antileukemic quassinoids from Brucea antidysenterica. J. Org. Chem., 1975, 40(5), 648-54.
18. Grieco, P. A.; Speake, J. D. Synthetic Studies on Quassinoids: Total Synthesis and Biological Evaluation of (+)-Des-Dchaparrinone. J. Org. Chem., 1998, 63(17), 5929-5936.
19. Polonsky, J. Quassinoid Bitter Principles. Fortschr. Chem. Org. Naturst., 1973, 30, 101-50.
20. Gurel, G.; Blaha, G.; Moore, P. B.; Steitz, T. A. U2504 determines the species specificity of the A-site cleft antibiotics: The structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J. Mol. Biol., 2009, 389(1), 146-56.
21. Wiseman, C. L.; Yap, H. Y.; Bedikian, A. Y.; Bodey, G. P.; Blumenschein, G. R. Phase II trial of bruceantin in metastatic breast carcinoma. Am. J. Clin. Oncol., 1982, 5(4), 389-91.
22. Arseneau, J. C.; Wolter, J. M.; Kuperminc, M.; Ruckdeschel, J. C. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma. Invest. New Drugs, 1983, 1(3), 239-42.
23. Wang, K.; Yin, X. M.; Chao, D. T.; Milliman, C. L.; Korsmeyer, S. J. BID: A novel BH3 domain-only death agonist. Genes Dev., 1996, 10(22), 2859-69.
24. Ly, J. D.; Grubb, D. R.; Lawen, A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis, 2003, 8(2), 115-28.
25. Cuendet, M.; Gills, J. J.; Pezzuto, J. M. Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation. Cancer Lett., 2004, 206(1), 43-50.
26. Wade, M.; Wahl, G. M. c-Myc, genome instability, and tumorigenesis: The devil is in the details. Curr. Top. Microbiol. Immunol., 2006, 302, 169-203.
27. Mata-Greenwood, E.; Cuendet, M.; Sher, D.; Gustin, D.; Stock, W.; Pezzuto, J. M. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia, 2002, 16(11), 2275-84.
28. Lau, S. T.; Lin, Z. X.; Zhao, M.; Leung, P. S. Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytother. Res., 2008, 22(4), 477-86.
29. Kim, I. H.; R., S.; Y., H.; K, T. Three novel quassinoids, javanicolides A and B, and javanicoside A, from seeds of Brucea javanica. Tetrahedron, 2003, 59 (50), 9985-9989.
30. Lau, S. T.; Lin, Z. X.; Leung, P. S. Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br. J. Cancer., 2010, 102(3), 583-93.
31. Kim, E. K.; Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta, 2010, 1802(4), 396-405.
32. Kim, H. J.; Hawke, N.; Baldwin, A. S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ., 2006, 13(5), 738-47.
33. Olson, J. M.; Hallahan, A. R. p38 MAP kinase: A convergence point in cancer therapy. Trends Mol. Med., 2004, 10(3), 125-9.
34. Luo, J. L.; Kamata, H.; Karin, M. IKK/NF-kappaB signaling: Balancing life and death-a new approach to cancer therapy. J. Clin. Invest., 2005, 115(10), 2625-32.
35. Escarcega, R. O.; Fuentes-Alexandro, S.; Garcia-Carrasco, M.; Gatica, A.; Zamora, A. The transcription factor nuclear factorkappa B and cancer. Clin. Oncol. (R. Coll. Radiol.), 2007, 19(2), 154-61.
36. Baud, V.; Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov., 2009, 8(1), 33-40.
37. Mata-Greenwood, E.; Daeuble, J. F.; Grieco, P. A.; Dou, J.; McChesney, J. D.; Mehta, R. G.; Kinghorn, A. D.; Pezzuto, J. M. Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12- dimethylbenz [a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture. J. Nat. Prod., 2001, 64(12), 1509-13.
38. Ling, V. Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 1997, 40(Suppl), S3-8.
39. Murakami, C.; Fukamiya, N.; Tamura, S.; Okano, M.; Bastow, K. F.; Tokuda, H.; Mukainaka, T.; Nishino, H.; Lee, K. H. Multidrugresistant cancer cell susceptibility to cytotoxic quassinoids, and cancer chemopreventive effects of quassinoids and canthin alkaloids. Bioorg. Med. Chem., 2004, 12(18), 4963-8.
40. Kuo, P. C.; Damu, A. G.; Lee, K. H.; Wu, T. S. Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia. Bioorg. Med. Chem., 2004, 12(3), 537-44.
41. Chan, K. L.; O'Neill M, J.; Phillipson, J. D.; Warhurst, D. C. Plants as Sources of Antimalarial Drugs. Part 31 Eurycoma longifolia. Planta Med., 1986, 52(2), 105-7.
42. Miyake, K.; Tezuka, Y.; Awale, S.; Li, F.; Kadota, S. Quassinoids from Eurycoma longifolia. J. Nat. Prod., 2009, 72(12), 2135-40.
43. Rosati, A.; Quaranta, E.; Ammirante, M.; Turco, M. C.; Leone, A.; De Feo, V. Quassinoids can induce mitochondrial membrane depolarisation and caspase 3 activation in human cells. Cell Death Differ., 2004, 11 Suppl 2, S216-8.
44. Kumar, D.; Bhat, Z. A.; Singh, P.; Shah, M. Y.; Bhujbal, S. S. Ailanthus excelsa roxb. is really a plant of heaven. Int. J. Pharmacol., 2010, 6, 535-550.
45. Lavhale, M. S.; Kumar, S.; Mishra, S. H.; Sitasawad, S. L. A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent. PLoS One, 2009, 4(4), e5365.
46. De Feo, V.; De Martino, L.; Quaranta, E.; Pizza, C. Isolation of phytotoxic compounds from tree-of-heaven (Ailanthus altissima swingle). J. Agric. Food Chem., 2003, 51(5), 1177-80.
47. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26(22), 3291-310.
48. Melillo, G. HIF-1: A target for cancer, ischemia and inflammation-too good to be true? Cell Cycle, 2004, 3(2), 154-5.
49. Giaccia, A.; Siim, B. G.; Johnson, R. S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov., 2003, 2(10), 803-11.
50. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3(10), 721-32.
51. Choi, K. S.; Bae, M. K.; Jeong, J. W.; Moon, H. E.; Kim, K. W. Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol., 2003, 36(1), 120-7.
52. Medema, R. H.; Bos, J. L. The role of p21ras in receptor tyrosine kinase signaling. Crit. Rev. Oncog., 1993, 4(6), 615-61.
53. De Benedetti, A.; Graff, J. R. eIF-4E expression and its role in malignancies and metastases. Oncogene, 2004, 23(18), 3189-99.
54. Watkins, S. J.; Norbury, C. J. Translation initiation and its deregulation during tumorigenesis. Br. J. Cancer., 2002, 86(7), 1023-7.
55. Graff, J. R.; Konicek, B. W.; Carter, J. H.; Marcusson, E. G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res., 2008, 68(3), 631-4.
56. Carlson, E. E. Natural products as chemical probes. ACS Chem. Biol., 2010, 5(7), 639-53.
57. Lee, K. H.; Okano, M.; Hall, I. H.; Brent, D. A.; Soltmann, B. Antitumor agents XLV: Bisbrusatolyl and brusatolyl esters and related compounds as novel potent antileukemic agents. J. Pharm. Sci., 1982, 71(3), 338-45.
58. Ohno, N.; Fukamiya, N.; Okano, M.; Tagahara, K.; Lee, K. H. Synthesis of cytotoxic fluorinated quassinoids. Bioorg. Med. Chem., 1997, 5(8), 1489-95.
59. Helson, L., McChesney, J., Bartyzel, P. In: In vitro cytotoxic activity of NBT-272, a novel quassinoid analog, Geneva, 2004; p. 171.
60. Stearns, D.; Chaudhry, A.; Abel, T. W.; Burger, P. C.; Dang, C. V.; Eberhart, C. G. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res., 2006, 66(2), 673-81.
61. Hiyama, E.; Hiyama, K.; Yokoyama, T.; Ishii, T. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: Correlation with prognosis of patients. J. Pediatr. Surg., 1991, 26(7), 838-43.
62. Takei, H.; Nguyen, Y.; Mehta, V.; Chintagumpala, M.; Dauser, R. C.; Adesina, A. M. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: Utility in predicting prognosis and survival. Laboratory investigation. J. Neurosurg. Pediatr., 2009, 3(1), 61-5.
63. Castelletti, D.; Fiaschetti, G.; Di Dato, V.; Ziegler, U.; Kumps, C.; De Preter, K.; Zollo, M.; Speleman, F.; Shalaby, T.; De Martino, D.; Berg, T.; Eggert, A.; Arcaro, A.; Grotzer, M. A. The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. Mol. Cancer Ther.; 2010; [Epub ahead of print].
64. Prendergast, G. C. Mechanisms of apoptosis by c-Myc. Oncogene, 1999, 18(19), 2967-87.
65. Eilers, M. Control of cell proliferation by Myc family genes. Mol. Cells, 1999, 9(1), 1-6.
66. Dang, C. V.; Kim, J. W.; Gao, P.; Yustein, J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer, 2008, 8(1), 51-6.
67. Schwab, M. MYCN in neuronal tumours. Cancer Lett., 2004, 204(2), 179-87.
68. Wolfer, A.; Wittner, B. S.; Irimia, D.; Flavin, R. J.; Lupien, M.; Gunawardane, R. N.; Meyer, C. A.; Lightcap, E. S.; Tamayo, P.; Mesirov, J. P.; Liu, X. S.; Shioda, T.; Toner, M.; Loda, M.; Brown, M.; Brugge, J. S.; Ramaswamy, S. MYC regulation of a "poorprognosis" metastatic cancer cell state. Proc. Natl. Acad. Sci. USA, 2010, 107(8), 3698-703.
69. Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. Modelling Myc inhibition as a cancer therapy. Nature, 2008, 455(7213), 679-83.
70. Karlsson, A.; Giuriato, S.; Tang, F.; Fung-Weier, J.; Levan, G.; Felsher, D. W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood, 2003, 101(7), 2797-803.
71. Grotzer, M. A.; Castelletti, D.; Fiaschetti, G.; Shalaby, T.; Arcaro, A. Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr. Cancer Drug Targets, 2009, 9(2), 176-88.
72. Sarkar, F. H.; Li, Y.; Wang, Z.; Kong, D. Cellular signaling perturbation by natural products. Cell. Signal., 2009, 21(11), 1541-7.